Teva's stock is a speculative buy with potential upside if biosimilars succeed, but risks remain high due to debt and ...

NEW YORK CITY, NY / ACCESS Newswire / February 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential ...

As an enterprise engaged in the development, manufacturing and commercialization of specialty plasma-derived therapeutics, ...

Teva Pharmaceutical Industries Ltd.'s bid to dismiss antitrust claims should be denied in a case where Mylan Pharmaceuticals Inc. alleges the company unlawfully delayed a generic version of a multiple ...

In high-income countries, more than 80% of children diagnosed with cancer will survive. Yet in some low- and middle-income ...

Granules India has announced that Sethu Madhavan Sankaran has resigned from the position of Senior Vice President & Head-API ...

Stanley Druckenmiller is a retired hedge fund manager of Duquesne Capital, which focuses on macro investment strategy. His fund constantly delivered high returns, and in 2010, when the fund failed to ...

Tom Hughes is the founder and CEO of Virtual Science AI.

The global generic oncology drugs market is set for consistent growth over the next decade, with sales anticipated to rise from USD 23,743.5 million in 2025 to USD 30,606.3 million by 2035, reflecting ...

The rising prevalence of respiratory diseases and technological advancements drive significant market growth.Pune, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Aerosol Drug Delivery Devices Market Size & Growth ...

Corneal Ulcer Treatment MarketThe global corneal ulcer treatment market is projected to grow at a CAGR of 5.2% from 2024 to 2034, reaching a market value of USD 1,601.1 million by 2034. In 2024, the ...

The "43rd Annual JP Morgan Healthcare Conference, January 13-16, 2025" report has been added to ResearchAndMarkets.com's offering.The 43rd Annual JP Morgan Healthcare Conference took place in San ...